In preclinical models, CDK4/6 inhibitors were associated with enhanced tumor antigen presentation, reduced proliferation of regulatory T cells (Tregs), and a lower expression of immune inhibitory receptors, such as PD-1 [50]. Here, CDK4 is linked to neoplasm.